Construction of tandem diabody (IL-6/CD20)-secreting human umbilical cord mesenchymal stem cells and its experimental treatment on diffuse large B cell lymphoma

BACKGROUND: More than 40% patients with diffuse large B cell lymphoma (DLBCL) experienced relapse or refractory (R/R) lymphoma after the standard first R-CHOP therapy. IL-6 was reportedly associated with chemotherapy resistance of rituximab. Further, mesenchymal stem cells (MSCs) are known as the po...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jiayi, Zhong, Minglu, Zhong, Weijie, Lan, Yanfei, Yuan, Zhaohu, Duan, Yuyou, Wei, Yaming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476312/
https://www.ncbi.nlm.nih.gov/pubmed/36104733
http://dx.doi.org/10.1186/s13287-022-03169-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476312/
https://www.ncbi.nlm.nih.gov/pubmed/36104733
http://dx.doi.org/10.1186/s13287-022-03169-4

Ejemplares similares